Sue Gail Eckhardt - Sep 16, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Director
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Sep 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/19/2022, 05:09 PM
Previous filing: Jun 2, 2022
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Award	$0	+8K		$0.00	8K	Sep 16, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Stock Option (right to buy)	Award	$0	+12K		$0.00	12K	Sep 16, 2022	Common Stock	12K	$7.35	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

Content

The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.